245 related articles for article (PubMed ID: 15984900)
21. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
[TBL] [Abstract][Full Text] [Related]
22. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin analogs for cancer treatment and diagnosis: an overview.
Scarpignato C; Pelosini I
Chemotherapy; 2001; 47 Suppl 2():1-29. PubMed ID: 11275699
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
25. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
[TBL] [Abstract][Full Text] [Related]
26. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
[TBL] [Abstract][Full Text] [Related]
27. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
28. Radiolabelled peptides for oncological diagnosis.
Laverman P; Sosabowski JK; Boerman OC; Oyen WJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S78-92. PubMed ID: 22388627
[TBL] [Abstract][Full Text] [Related]
29. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
30. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
31. Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog.
Edelman MJ; Clamon G; Kahn D; Magram M; Lister-James J; Line BR
J Thorac Oncol; 2009 Dec; 4(12):1550-4. PubMed ID: 19884860
[TBL] [Abstract][Full Text] [Related]
32. Radiopharmaceutical development of radiolabelled peptides.
Fani M; Maecke HR
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S11-30. PubMed ID: 22388624
[TBL] [Abstract][Full Text] [Related]
33. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.
Smith CJ; Volkert WA; Hoffman TJ
Nucl Med Biol; 2005 Oct; 32(7):733-40. PubMed ID: 16243649
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
35. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
Panigone S; Nunn AD
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):310-21. PubMed ID: 17043628
[TBL] [Abstract][Full Text] [Related]
36. Radiopeptide imaging and therapy in the United States.
Graham MM; Menda Y
J Nucl Med; 2011 Dec; 52 Suppl 2():56S-63S. PubMed ID: 22144556
[TBL] [Abstract][Full Text] [Related]
37. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview.
Warner RR; O'dorisio TM
Semin Nucl Med; 2002 Apr; 32(2):79-83. PubMed ID: 11965602
[TBL] [Abstract][Full Text] [Related]
38. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
39. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.
Decristoforo C; Maina T; Nock B; Gabriel M; Cordopatis P; Moncayo R
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1211-9. PubMed ID: 12845487
[TBL] [Abstract][Full Text] [Related]
40. Rationale for the use of radiolabelled peptides in diagnosis and therapy.
Koopmans KP; Glaudemans AW
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S4-10. PubMed ID: 22388630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
